Last reviewed · How we verify
highly active antiretroviral therapy (HAART)
HAART combines multiple antiretroviral drugs to inhibit different stages of the HIV life cycle, thereby reducing viral replication and improving immune function.
Highly Active Antiretroviral Therapy (HAART) is a combination of antiretroviral drugs used to treat HIV infection. HAART works by inhibiting the replication of the virus in the body, thereby reducing the viral load and improving immune function. Developed by the National Institute of Allergy and Infectious Diseases (NIAID), HAART has been pivotal in transforming HIV from a fatal disease to a manageable chronic condition. The therapy typically consists of at least three different drugs from two or more classes, which helps prevent the development of drug-resistant strains of the virus. Despite its effectiveness, HAART can have significant side effects, and careful monitoring is required to manage these issues.
At a glance
| Generic name | highly active antiretroviral therapy (HAART) |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | Antiretroviral |
| Target | HIV enzymes and processes |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
HAART uses a combination of drugs that target different stages of the HIV life cycle, such as reverse transcriptase inhibitors, protease inhibitors, and integrase inhibitors, to effectively suppress viral replication.
Approved indications
Common side effects
- Nausea
- Headache
- Diarrhea
- Fatigue
- Rash
Key clinical trials
- Efficacy and Safety of Doravirine in the Rapid Initiation (PHASE4)
- The University of Zimbabwe College of Health Science (UZ-CHS) BIRTH COHORT Study
- Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load (PHASE4)
- Antiretroviral Therapy for Acute and Chronic HIV Infection (PHASE3)
- ARVs to Prevent Breastmilk HIV:Viral and Immune Responses (PHASE2)
- Trends of Morbidity and Mortality Among Thai HIV-infected and HIV-uninfected Patients: a Five-year Prospective Cohort Study
- Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis (NA)
- A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: